Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
CSF1R positive Sorafenib Hodgkin's lymphoma sensitive detail...
Unknown unknown Edicotinib Hodgkin's lymphoma not applicable detail...
Unknown unknown Dezapelisib Hodgkin's lymphoma not applicable detail...
Unknown unknown Dezapelisib + Itacitinib Hodgkin's lymphoma not applicable detail...
Unknown unknown Brentuximab vedotin + Umbralisib Hodgkin's lymphoma not applicable detail...
CSF1R positive N/A Hodgkin's lymphoma not applicable detail...
Unknown unknown Nivolumab Hodgkin's lymphoma not applicable detail...
Unknown unknown Ixazomib Hodgkin's lymphoma not applicable detail...
Unknown unknown AZD7762 + Ixazomib Hodgkin's lymphoma not applicable detail...
Unknown unknown Ixazomib + JQ1 Hodgkin's lymphoma not applicable detail...
Unknown unknown Idelalisib Hodgkin's lymphoma not applicable detail...
Unknown unknown Brentuximab vedotin Hodgkin's lymphoma not applicable detail...
Unknown unknown Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Hodgkin's lymphoma not applicable detail...
Unknown unknown Pembrolizumab Hodgkin's lymphoma not applicable detail...
Unknown unknown Camidanlumab Tesirine Hodgkin's lymphoma not applicable detail...
Unknown unknown Tenalisib Hodgkin's lymphoma not applicable detail...
Unknown unknown Alisertib + Vorinostat Hodgkin's lymphoma not applicable detail...
Unknown unknown Varlilumab Hodgkin's lymphoma not applicable detail...
Unknown unknown Darinaparsin + U0126 Hodgkin's lymphoma not applicable detail...
Unknown unknown Darinaparsin + Selumetinib Hodgkin's lymphoma not applicable detail...
Unknown unknown Darinaparsin Hodgkin's lymphoma not applicable detail...
Unknown unknown Sirolimus + Vorinostat Hodgkin's lymphoma not applicable detail...
Unknown unknown Everolimus + Vorinostat Hodgkin's lymphoma not applicable detail...
Unknown unknown CC-90011 Hodgkin's lymphoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00513474 Phase I Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant Completed USA 0
NCT00576654 Phase I Irinotecan Veliparib Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT00602693 Phase I Sirolimus Allopurinol + Cyclophosphamide + Fludarabine T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed USA 0
NCT00838955 Phase II Temsirolimus Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma Terminated USA 0
NCT00857389 Phase II Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Completed USA 0
NCT01028716 Phase II Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting USA 0
NCT01032148 Phase I Panobinostat Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma Terminated USA 0
NCT01076543 Phase Ib/II Lenalidomide + Temsirolimus Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Completed USA 0
NCT01169636 Phase Ib/II Panobinostat Pegfilgrastim Carboplatin + Etoposide + Ifosfamide Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma Completed USA 0
NCT01196208 Expanded access Brentuximab vedotin A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 No longer available USA 14
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Completed USA 1
NCT01333046 Phase I MultiTAA-specific T cells Azacitidine + MultiTAA-specific T cells Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL (TACTAL) Recruiting USA 0
NCT01476839 Phase I Basiliximab + Carmustine + Cytarabine + Etoposide + Melphalan + Yttrium Y 90 Basiliximab Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma Active, not recruiting USA 0
NCT01592370 Phase I Nivolumab Ipilimumab Lirilumab Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma Active, not recruiting USA 5
NCT01609816 Phase Ib/II Dasatinib Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant Terminated USA 0
NCT01621477 Phase II Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant Terminated USA 0
NCT01701986 Phase Ib/II Tacrolimus Rituximab Filgrastim Mycophenolate mofetil anti-thymocyte globulin Busulfan + Clofarabine + Gemcitabine Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas Recruiting USA 0
NCT01716806 Phase II Brentuximab vedotin + Nivolumab Bendamustine + Brentuximab vedotin Brentuximab vedotin + Dacarbazine Brentuximab vedotin A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL) Recruiting USA | CAN 0
NCT01742988 Phase Ib/II Bendamustine + CUDC-907 + Rituximab CUDC-907 + Rituximab CUDC-907 CUDC-907 + Venetoclax Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma Active, not recruiting USA 0
NCT01745354 Phase I SD-101 Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) Terminated USA 0
NCT01811368 Phase II anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Recruiting USA 0
NCT01822509 Phase I Ipilimumab + Nivolumab Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Active, not recruiting USA 0
NCT01896999 Phase I Brentuximab vedotin + Ipilimumab Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Recruiting USA 0
NCT01897012 Phase I Romidepsin Alisertib Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Completed USA 0
NCT01905813 Phase I Dezapelisib + Itacitinib Dezapelisib Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies Active, not recruiting USA 0
NCT01949883 Phase I CPI-0610 A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Completed 0
NCT01953692 Phase I Pembrolizumab A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) Completed 0
NCT01983969 Phase Ib/II Rituximab Dexamethasone Busulfan + Melphalan Azacitidine + Gemcitabine + Vorinostat Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Completed USA 0
NCT02018861 Phase I Itacitinib Itacitinib + Parsaclisib Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide Parsaclisib A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies Active, not recruiting USA 0
NCT02061761 Phase Ib/II Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies Active, not recruiting USA | CAN 0
NCT02091063 Phase Ib/II Ricolinostat ACY-1215 for Relapsed/Refractory Lymphoid Malignancies Completed USA 0
NCT02098512 Phase Ib/II Brentuximab vedotin Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients Unknown status USA 0
NCT02104427 Phase II Burixafor Filgrastim PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients Completed USA 0
NCT02130869 Phase I Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas Completed USA 0
NCT02164006 Phase I Umbralisib Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients Completed USA 0
NCT02181218 Phase I Pegfilgrastim Romidepsin Dexamethasone + Gemcitabine + Oxaliplatin Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas Completed USA 0
NCT02181738 Phase II Nivolumab Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205) Active, not recruiting USA | CAN 8
NCT02200380 Phase II Plerixafor CDX-301 A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs Terminated USA 0
NCT02203903 Phase I MultiTAA-specific T cells Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) Recruiting USA 0
NCT02208037 Phase II Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Completed USA 0
NCT02227199 Phase Ib/II Brentuximab vedotin + Carboplatin + Etoposide + Ifosfamide Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE) Active, not recruiting USA 0
NCT02254239 Phase I Everolimus Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Terminated USA 0
NCT02287311 Phase I LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes Cyclophosphamide + Fludarabine Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) Recruiting USA 0
NCT02304458 Phase Ib/II Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Active, not recruiting USA | CAN 0
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Completed USA 1
NCT02332668 Phase Ib/II Pembrolizumab A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) Recruiting USA 9
NCT02343666 Phase I Filgrastim Carmustine Plerixafor O6-benzylguanine HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection Withdrawn USA 0
NCT02362997 Phase II Pembrolizumab Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL Active, not recruiting USA 0
NCT02376699 Phase I Pembrolizumab + SEA-CD40 SEA-CD40 Safety Study of SEA-CD40 in Cancer Patients Recruiting USA 0
NCT02398240 Phase II Brentuximab vedotin + Doxorubicin + Rituximab + Vincristine Sulfate Brentuximab vedotin + Doxorubicin + Vincristine Sulfate Brentuximab for Newly Diagnosed Hodgkin Disease Recruiting USA 0
NCT02408042 Phase Ib/II Rituximab Carboplatin + Etoposide + Ifosfamide Pembrolizumab Brentuximab vedotin Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) Withdrawn USA 0
NCT02429375 Phase Ib/II Brentuximab vedotin + Mocetinostat Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting USA 0
NCT02453594 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) Active, not recruiting 0
NCT02541604 Phase I Atezolizumab A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors Terminated USA | CAN 9
NCT02572167 Phase Ib/II Brentuximab vedotin + Nivolumab A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting USA 0
NCT02576496 Phase I Tinostamustine Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Recruiting USA 5
NCT02595866 Phase I Pembrolizumab Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Recruiting USA 0
NCT02603419 Phase I Avelumab Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS) Terminated USA 2
NCT02613598 Phase I Bortezomib + Ruxolitinib Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma Recruiting USA 0
NCT02624258 Phase I RNA CART19 cells Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma Terminated USA 0
NCT02651662 Phase I Cemiplimab Cemiplimab + Odronextamab Study of REGN2810 and REGN1979 in Patients With Lymphoma Active, not recruiting USA 2
NCT02663297 Phase I ATLCAR.CD30 cells Administration of T Lymphocytes for Prevention of Relapse of Lymphomas Recruiting USA 0
NCT02665650 Phase I AFM13 + Pembrolizumab Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Completed USA 1
NCT02684292 Phase III Brentuximab vedotin Pembrolizumab Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) Active, not recruiting 0
NCT02690545 Phase Ib/II ATLCAR.CD30 cells Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL Recruiting USA 0
NCT02701673 Phase Ib/II Azacitidine Pyridoxine Gemcitabine Belinostat Busulfan Melphalan Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma Withdrawn 0
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting USA 0
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma Recruiting USA 0
NCT02744612 Phase II Brentuximab vedotin + Ibrutinib Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Suspended USA 0
NCT02758717 Phase II Brentuximab vedotin + Nivolumab Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma Active, not recruiting USA 0
NCT02763254 Phase II CMD-003 Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (CIVIC) Terminated USA 0
NCT02797470 Phase Ib/II Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Recruiting USA 0
NCT02824029 Phase II Ibrutinib Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Unknown status USA 0
NCT02867618 Phase Ib/II Carfilzomib + Umbralisib Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma Terminated USA 0
NCT02869633 Phase II Ibrutinib Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant Active, not recruiting USA 0
NCT02875067 Phase Ib/II Lenalidomide + Pembrolizumab Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma Terminated USA 0
NCT02890758 Phase I ALT-803 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Recruiting USA 0
NCT02917083 Phase I ATLCAR.CD30 cells + Cyclophosphamide + Fludarabine CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (RELY-30) Recruiting USA 0
NCT02927769 Phase II Brentuximab vedotin + Nivolumab Bendamustine + Brentuximab vedotin A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744) Recruiting USA | CAN 9
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Terminated USA 0
NCT02940301 Phase II Ibrutinib + Nivolumab Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Recruiting USA 0
NCT02960646 Phase I Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting USA 0
NCT02961816 Phase II Pyridoxine Busulfan + Gemcitabine + Melphalan + Panobinostat Dexamethasone + Filgrastim + Palifermin + Rituximab Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma Withdrawn 0
NCT02973113 Phase I EB-VST cells + Nivolumab Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE) Active, not recruiting USA 0
NCT03013933 Phase I Brentuximab vedotin + Cyclosporine + Verapamil Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Recruiting USA 0
NCT03015896 Phase Ib/II Lenalidomide + Nivolumab Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Recruiting USA 0
NCT03016871 Phase II Nivolumab Carboplatin + Etoposide + Ifosfamide + Nivolumab Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL Recruiting USA 0
NCT03033914 Phase I Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Bleomycin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma Recruiting USA 0
NCT03049449 Phase I ATLCAR.CD30 cells Cyclophosphamide + Fludarabine T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Recruiting USA 0
NCT03057795 Phase II Brentuximab vedotin + Nivolumab Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma Active, not recruiting USA 0
NCT03077828 Phase II Carboplatin + Etoposide + Ifosfamide + Pembrolizumab Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Recruiting USA 0
NCT03120676 Phase II Atezolizumab Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma Terminated USA 0
NCT03138499 Phase III Brentuximab vedotin Brentuximab vedotin + Nivolumab Phase III Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, Active, not recruiting USA 2
NCT03150329 Phase I Pembrolizumab + Vorinostat Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma Recruiting USA 0
NCT03179917 Phase II Pembrolizumab Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma Recruiting USA 0
NCT03179930 Phase II Entinostat + Pembrolizumab Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas Recruiting USA 0
NCT03226249 Phase II Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma Active, not recruiting USA 0
NCT03233347 Phase II Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma Recruiting USA 0
NCT03236935 Phase I L-NMMA + Pembrolizumab Phase Ib of L-NMMA and Pembrolizumab Recruiting USA 0
NCT03259503 Phase Ib/II Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas Recruiting USA 0
NCT03331341 Phase II Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma Recruiting USA 0
NCT03357757 Phase II Avelumab + Valproic acid Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) Recruiting CAN 0
NCT03407144 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Pembrolizumab + Prednisone + Vincristine Sulfate Bleomycin + Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) Recruiting USA 12
NCT03432741 Phase I Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Suspended USA 0
NCT03436862 Phase II Nivolumab Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression Recruiting USA 0
NCT03471351 Phase Ib/II Pembrolizumab + Tenalisib Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL Terminated USA 0
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Recruiting USA 0
NCT03495713 Phase II Nivolumab RADVAX FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS Suspended USA 0
NCT03598608 Phase Ib/II MK-4280 + Pembrolizumab Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) Recruiting USA | CAN 4
NCT03602157 Phase I ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL Recruiting USA 0
NCT03618550 Phase II Doxorubicin + Gemcitabine + Pembrolizumab + Vinorelbine Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma Recruiting USA 0
NCT03646123 Phase II Brentuximab vedotin + Dacarbazine + Doxorubicin + Filgrastim + Vinblastine Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Recruiting USA 0
NCT03674411 Phase II Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Active, not recruiting USA 0
NCT03681561 Phase Ib/II Nivolumab + Ruxolitinib Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma Recruiting USA 0
NCT03697408 Phase Ib/II Everolimus + Itacitinib Itacitinib + Everolimus in Hodgkin Lymphoma Recruiting USA 0
NCT03712202 Phase II Nivolumab Brentuximab vedotin + Nivolumab Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Bleomycin + Dacarbazine + Doxorubicin + Vinblastine Brentuximab Vedotin and Nivolumab in Treating Participants With Early Stage Classic Hodgkin Lymphoma Recruiting USA 0
NCT03739606 Phase II Flotetuzumab Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Withdrawn 0
NCT03739619 Phase Ib/II Bendamustine + Gemcitabine + Nivolumab Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Active, not recruiting USA 0
NCT03776864 Phase II Pembrolizumab + Umbralisib Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Recruiting USA 0
NCT03778073 Phase I Cosibelimab Study of TG-1501 in Subjects With Relapsed or Refractory Lymphoma Recruiting USA 0
NCT03809624 Phase I INBRX-105 Study of INBRX-105 in Patients With Solid Tumors (PDL1x41BB) Recruiting USA 0
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Recruiting USA 0
NCT03843294 Phase I MultiTAA-specific T cells + Nivolumab Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma Recruiting USA 0
NCT03885947 Phase I Cyclophosphamide + Fludarabine + Thiotepa VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies Active, not recruiting USA 0
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Recruiting USA | CAN 2
NCT03907488 Phase III Pegfilgrastim Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Filgrastim Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma Recruiting USA 0
NCT03920631 Phase I Nivolumab Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) Recruiting USA 0
NCT03921879 Phase I OT-82 Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma Recruiting USA 0
NCT03925935 Phase I AB-205 Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation Recruiting USA 0
NCT03947255 Phase II Brentuximab vedotin A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma Recruiting USA 0
NCT03983668 Phase Ib/II Pembrolizumab + QbG10 CMP-001 for Relapsed and Refractory Lymphoma Recruiting USA 0
NCT04016116 Phase II Pembrolizumab + Ruxolitinib Pembrolizumab Dual PD-1 and JAK2 Inhibition in Hematological Malignancies Withdrawn USA 0
NCT04052997 Phase II Camidanlumab Tesirine Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting USA | CAN 9
NCT04074746 Phase I Cyclophosphamide + Fludarabine AFM13 Bispecific Antibody AFM13 Combined With NK Cells for Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Recruiting USA 0
NCT04134325 Phase I Nivolumab Pembrolizumab Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma Recruiting USA 0
NCT04160195 Phase I Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma Suspended USA 0
NCT04233697 Phase I Copanlisib + Romidepsin Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma Withdrawn 0
NCT04254107 Phase I SGN-TGT Pembrolizumab + SGN-TGT A Safety Study of SGN-TGT in Patients With Advanced Cancer Recruiting USA 4
NCT04318080 Phase II Tislelizumab Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma Recruiting USA 4
NCT04423029 Phase Ib/II DF6002 + Pembrolizumab DF6002 Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Recruiting USA 0
NCT04464798 Phase I Iberdomide Iberdomide + Obinutuzumab Iberdomide + Rituximab A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas Not yet recruiting USA 3
NCT04510636 Phase II Bendamustine + Pembrolizumab Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma Not yet recruiting CAN 0
NCT04561206 Phase II Brentuximab vedotin + Nivolumab Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed Classical Hodgkin Lymphoma Not yet recruiting USA 0
NCT04681105 Phase I Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Recruiting USA 0